BrainCool AB

BrainCool AB

BrainCool AB was founded in 2008 and is headquartered in Lund, Sweden. The company emerged from research at Lund University on therapeutic hypothermia and has since developed a portfolio of cooling platforms for acute medical applications. The company operates primarily through two platforms: RhinoChill, a noninvasive nasal cooling device for neuroprotection, and PolarCool, a portable cooling system for management of sports-related concussions and for dermatology applications. BrainCool listed on the Nasdaq First North Growth Market in 2015 to fund clinical trials and commercialization. Products target hospital emergency departments, intensive care units, and sports medicine clinics. Geographic focus includes Europe and the United States, with regulatory clearance from the FDA for the RhinoChill system. As of 2025, BrainCool had fewer than 50 employees and relied on grant funding from the European Union's Horizon 2020 program. The company has not disclosed total capital raised or revenue. In August 2022, BrainCool announced a partnership with the NFL to study the PolarCool system for concussion management (per the firm, August 2022). No charitable or family-office entities are associated with the company. BrainCool is a publicly traded entity, not a family office. Its board of directors includes representatives from academia and the medical device industry. The company distinguishes itself through a focus on noninvasive, portable cooling technology for indications where hypothermia has shown therapeutic benefit but existing devices are invasive or bulky.